Nkarta, Inc. Stock Price, News & Analysis

Nkarta, Inc. (Nasdaq: NKTX) announced that it will present four posters at the American Association for Cancer Research (AACR) Annual Meeting from April 8 to 13, 2022. The posters will cover topics such as the development of CAR NK cell therapies and preclinical models for multiple myeloma, showcasing the company's advancements in engineered NK cell therapies. Nkarta aims to leverage its proprietary technologies for broad outpatient treatment access. All abstracts will be available on the AACR e-poster website starting April 8, 2022.

Nkarta, a biopharmaceutical company focused on engineered natural killer (NK) cell therapies for cancer, will present at three key investor conferences:

• SVB Leerink 11th Annual Global Healthcare Conference on February 17, 2022, at 1:40 p.m. ET.
• Cowen 42nd Annual Health Care Conference on March 7, 2022, at 10:30 a.m. ET.
• Oppenheimer 32nd Annual Healthcare Conference on March 16, 2022, at 10:00 a.m. ET.

Webcasts of these presentations will be available on the company's website, with replays archived for approximately four weeks.

Nkarta, Inc. (Nasdaq: NKTX) announced that the FDA granted orphan drug designation (ODD) to NKX101 for treating acute myeloid leukemia (AML). This investigational NK cell therapy leverages the NKG2D receptor to enhance cancerous cell targeting. With a five-year survival rate of only 26% in AML patients, ODD emphasizes the urgent need for alternative treatments. NKX101 is undergoing a Phase 1 clinical trial for relapsed/refractory AML. The ODD may provide Nkarta with development incentives, including potential tax credits and marketing exclusivity upon FDA approval.

Nkarta, Inc. (NASDAQ: NKTX) presented a trial in progress poster for NKX019, an investigational therapy targeting relapsed and refractory B-cell malignancies, at the 63rd ASH Annual Meeting. NKX019 utilizes allogeneic NK cells engineered to express a CAR targeting CD19. The Phase 1 clinical trial is evaluating safety and anti-tumor activity. Initial data is expected in 2022. The treatment aims to overcome limitations of existing therapies. B-cell cancers remain a significant health challenge, with over half a million new non-Hodgkin lymphoma cases diagnosed yearly.

Nkarta, Inc. (Nasdaq: NKTX) presented four preclinical data abstracts at the SITC 36th Annual Meeting, highlighting advancements in its NK cell therapy platform. The research demonstrates enhanced NK cell ability to target tumors through innovative approaches, including gene-editing strategies. Notably, the combination of CD70 CAR and CISH knockout showed increased cytotoxicity and persistence of NK cells. Additionally, methods for large-scale expansion of NK cells could lead to efficient off-the-shelf therapies. These findings underscore Nkarta's ongoing collaboration with CRISPR Therapeutics and its commitment to advancing cancer treatments.

Nkarta, Inc. (Nasdaq: NKTX) reported its third-quarter 2021 results, highlighting key advancements in its clinical trials. The company anticipates initial data from the Phase 1 trial of NKX101 in AML and MDS in the first half of 2022, while also announcing the successful dosing of patients in the NKX019 trial for B cell malignancies. Financially, Nkarta had cash equivalents of $259.8 million as of September 30, 2021, with R&D expenses totaling $16.6 million. The net loss for the quarter was $22.4 million, or $0.68 per share, but guidance suggests operational funding through at least the second half of 2023.

Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical firm focused on engineered NK cell therapies for cancer, announced its participation in several upcoming investor conferences. Notable events include the Cowen 5th Annual IO Next Summit on November 15, 2021, at 11:15 a.m. ET, the Stifel 2021 Virtual Healthcare Conference on November 17, 2021, at 2:00 p.m. ET, and the Evercore ISI 4th Annual HealthCONx Conference on December 1, 2021, at 4:20 p.m. ET. Each session will be webcast live and available for replay on Nkarta's website.

Nkarta, Inc. announced the initiation of a Phase 1 clinical trial for NKX019 aimed at treating advanced B-cell malignancies. This investigational NK cell immunotherapy targets CD19, with initial data expected in 2022. The company also updated its timeline for NKX101, another CAR NK cell therapy for AML and MDS, anticipating initial data in the first half of 2022. Nkarta is producing the NKX019 clinical supply at its South San Francisco facility, aiming to provide an effective off-the-shelf treatment option for patients.

Nkarta, Inc. (Nasdaq: NKTX) announced four upcoming presentations at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting, detailing advancements in engineered natural killer (NK) cell therapies. Key highlights include the potential clinical applications of CRISPR/Cas9 technologies and donor selection algorithms for next-generation NK cells. The presentations aim to enhance the expansion of engineered NK cells, potentially allowing a single donor to supply a lifetime's worth of commercial product. Full abstracts will be available on November 9, 2021.